Iksuda to Share Early Phase 1 Findings on IKS014 in Oesophageal Cancer at ASCO GI 2026
MM Desk
8 January, 2026
Iksuda Therapeutics, a biotechnology company focused on next-generation antibody drug conjugates (ADCs), has announced that